Analysts Offer Insights on Healthcare Companies: FibroGen (FGEN), Karyopharm Therapeutics (KPTI) and Day One Biopharmaceuticals (DAWN)
TipRanksFeb 26 22:30 ET
Sell Rating on FibroGen Amid Skepticism Over Clinical Outcomes and Drug Efficacy
TipRanksFeb 13 22:45 ET
Analysts Offer Insights on Healthcare Companies: FibroGen (FGEN), BioNTech SE (BNTX) and Sensei Biotherapeutics (SNSE)
TipRanksNov 6, 2023 22:50 ET
BofA Downgrades FibroGen to Underperform, Cites Unfavorable Catalysts
Seeking AlphaAug 8, 2023 16:29 ET
B of A Securities Downgrades FibroGen to Underperform, Lowers Price Target to $2
BenzingaAug 8, 2023 08:49 ET
FibroGen Analyst Ratings
BenzingaAug 8, 2023 08:48 ET
BofA Securities Downgrades FibroGen to Neutral From Buy, Lowers Price Target to $4 From $29
MT NewswiresJun 27, 2023 10:03 ET
Goldman Sachs Maintains Sell on FibroGen, Lowers Price Target to $2
BenzingaJun 27, 2023 08:10 ET
Analysts Have Conflicting Sentiments on These Healthcare Companies: MoonLake Immunotherapeutics (MLTX), Option Care Health (OPCH) and FibroGen (FGEN)
TipRanksJun 26, 2023 19:10 ET
FibroGen (FGEN) Receives a Sell From Goldman Sachs
TipRanksJun 26, 2023 15:05 ET
Stifel Downgrades FibroGen to Hold From Buy, Cuts Price Target to $11 From $28
MT NewswiresJun 26, 2023 13:28 ET
FibroGen (FGEN) Receives a Sell From Goldman Sachs
TipRanksJun 7, 2023 10:25 ET
Analysts' Opinions Are Mixed on These Healthcare Stocks: Tonix Pharma (TNXP), ANI Pharmaceuticals (ANIP) and FibroGen (FGEN)
TipRanksMay 9, 2023 08:37 ET
Goldman Sachs Remains a Sell on FibroGen (FGEN)
TipRanksMay 5, 2023 14:56 ET
Goldman Sachs Sticks to Their Sell Rating for FibroGen (FGEN)
TipRanksMay 2, 2023 00:15 ET
Analyst Ratings for FibroGen
BenzingaFeb 28, 2023 14:00 ET
Cowen Adjusts Price Target on FibroGen to $25 From $15, Maintains Market Perform Rating
MT NewswiresFeb 28, 2023 08:43 ET
Cowen & Co. Maintains Market Perform on FibroGen, Raises Price Target to $25
BenzingaFeb 28, 2023 08:17 ET
Analysts Offer Insights on Healthcare Companies: Perrigo Company (PRGO), FibroGen (FGEN) and Disc Medicine (IRON)
TipRanksFeb 28, 2023 06:46 ET
Goldman Sachs Increases Price Target on FibroGen to $16 From $9, Maintains Sell Rating
MT NewswiresFeb 21, 2023 11:03 ET
No Data
No Data